Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050921 · ClinicalTrials.gov registry record · NA
Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00050921 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 60 participants.
The verdict
NCT00050921, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is designed to evaluate the ability of growth hormone (GH, also known as somatropin) to increase CD4+ cell counts in patients taking anti-HIV drugs. The study is targeted toward patients with low levels of HIV who continue to have low CD4+ cell counts.
Interventions
- DRUG somatropin
- BIOLOGICAL Hepatitis A virus, inactivated
- DRUG Keyhole-Limpet Hemocyanin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Est. Completion | 2005-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050921
The ClinicalTrials.gov registry entry for NCT00050921 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which somatropin is the first listed.
NCT00050921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050921 about?
NCT00050921 is a clinical study titled "Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs". This study is designed to evaluate the ability of growth hormone (GH, also known as somatropin) to increase CD4+ cell counts in patients taking anti-HIV drugs. The study is targeted toward patients with low levels of HIV who continue to have low CD4+ cell counts.
What is the current status of trial NCT00050921?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00050921?
The interventions under investigation include: somatropin (DRUG), Hepatitis A virus, inactivated (BIOLOGICAL), Keyhole-Limpet Hemocyanin (DRUG).
Who is sponsoring clinical trial NCT00050921?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.